share_log

Lineage Cell Therapeutics, Inc. Highlights Presentation Of RG6501 Phase 1/2a Data At ARVO 2023

Benzinga ·  Apr 26, 2023 20:20
  • Preliminary Evidence of Durable Anatomical and Functional Improvements Following Administration of OpRegen Cells
  • Extensive OpRegen Surgical Bleb Coverage of Areas of GA May Be Critical for Optimizing Patient Outcomes
  • OCT Imaging With Segmentation Analysis is Advantageous in Assessment of Retinal Integrity Post-Treatment
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment